2024
Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers
Schejter‐Margalit T, Binyamin N, Thaler A, Maidan I, Cedarbaum J, Orr‐Urtreger A, Weisz M, Goldstein O, Giladi N, Mirelman A, Kizony R. Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers. European Journal Of Neurology 2024, 31: e16327. PMID: 38743695, PMCID: PMC11235808, DOI: 10.1111/ene.16327.Peer-Reviewed Original ResearchKnown-groups validityWeekly Calendar Planning ActivityColor Trails TestActivities of Daily Living ScaleKnown-groups construct validityIdiopathic PDPhysical Activity ScaleDaily Living ScaleEngland Activities of Daily Living ScaleNonmanifesting carriersPD to healthy controlsIdiopathic PD groupMontreal Cognitive AssessmentEcological validitySE-ADLActivity ScaleCompare personsConstruct validityOutcome measuresConvergent validityCognitive AssessmentGBA carriersEngland ActivitiesParkinson's diseaseCognitive tests
2023
P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Vieira D, Rosenberg P, Herrmann N, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. P104: Heterogeneity of Response to methylphenidate in apathetic patients in the ADMET 2 Trial. International Psychogeriatrics 2023, 35: 125-126. DOI: 10.1017/s1041610223002557.Peer-Reviewed Original ResearchPotential predictors of treatment outcomePredictors of treatment outcomeResponse to methylphenidateClinically significant apathyAlzheimer's Disease Cooperative Study ActivitiesMedium effect sizeMonths of methylphenidateAlzheimer's diseaseNPI-aMethylphenidate treatmentSignificant apathyApathetic patientsBaseline anxietyAD participantsMethylphenidatePotential predictorsActivities of Daily Living ScaleCompared to placeboNeuropsychiatric symptomsIndex scoreDaily Living ScaleAlzheimer's Disease Cooperative Study Activities of Daily Living ScaleApathyEffect sizeLiving ScaleHeterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial
Lanctôt K, Rivet L, Tumati S, Perin J, Sankhe K, Vieira D, Mintzer J, Rosenberg P, Shade D, Lerner A, Padala P, Brawman-Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Padala K, Herrmann N. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial. American Journal Of Geriatric Psychiatry 2023, 31: 1077-1087. PMID: 37385898, PMCID: PMC10765607, DOI: 10.1016/j.jagp.2023.06.002.Peer-Reviewed Original ResearchConceptsDiastolic blood pressureBlood pressureClinical predictorsDisease patientsAlzheimer's Disease Cooperative Study-ActivitiesHg diastolic blood pressureOptimal diastolic blood pressureMulti-center clinical trialDaily Living ScaleYears of ageAlzheimer's disease patientsHeterogeneity of responseApathy domainApathetic patientsClinical trialsFunctional impairmentTreatment benefitSignificant apathyLiving ScaleImpaired functionBaseline anxietyCholinesterase inhibitorsMedium effect sizeMethylphenidatePotential predictors
2022
Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial
Lanctôt K, Perin J, Vieira D, Rosenberg P, Herrmann N, Shade D, Lerner A, Padala P, Brawman‐Mintzer O, van Dyck C, Porsteinsson A, Craft S, Levey A, Mintzer J. Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.066932.Peer-Reviewed Original ResearchHeterogeneity of responseAlzheimer's diseaseAD patientsBaseline anxietyPlacebo-controlled clinical trialApathetic AD patientsDaily Living ScaleCommon neuropsychiatric symptomsLow functional capacityLower functional capabilityNPI apathy scoreLower baseline anxietyAD medicationsDifference of changesNeuropsychiatric InventoryNeuropsychiatric symptomsApathetic patientsClinical trialsMonth visitTreatment outcomesEffect differencesSignificant apathyLiving ScaleApathy scoresFunctional capacitySensory stimulation improves daily functions in Alzheimer’s disease
Cimenser A, Hempel E, Konisky A, Vaughan B, Megerian J, Malchano Z, Hajos M. Sensory stimulation improves daily functions in Alzheimer’s disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.060270.Peer-Reviewed Original ResearchADCS-ADLTreatment groupsFunctional abilityAlzheimer's diseaseSensory stimulationPlacebo groupAlzheimer's Disease Cooperative Study-ActivitiesDaily functional abilitiesAbnormal neuronal activityDaily Living ScalePlacebo group participantsGamma oscillationsGroup participantsSynchronized gamma oscillationsAbnormal neuronal functionHz gamma oscillationsTreatment group participantsClinical trialsDisease progressionPathological markersFunctional declineDifferent functional abilitiesLiving ScaleNeuronal activityDaily functionLecanemab in Early Alzheimer’s Disease
van Dyck C, Swanson C, Aisen P, Bateman R, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer L, Iwatsubo T. Lecanemab in Early Alzheimer’s Disease. New England Journal Of Medicine 2022, 388: 9-21. PMID: 36449413, DOI: 10.1056/nejmoa2212948.Peer-Reviewed Original ResearchConceptsEarly Alzheimer's diseasePositron emission tomographyDisease Assessment ScaleAlzheimer's diseaseAmyloid burdenAlzheimer's Disease Cooperative Study-ActivitiesAmyloid-related imaging abnormalitiesKey secondary end pointEnd pointAlzheimer's Disease Assessment ScaleClinical Dementia Rating SumHumanized IgG1 monoclonal antibodyMarkers of amyloidInfusion-related reactionsPrimary end pointSecondary end pointsCerebrospinal fluid testingPhase 3 trialBrain amyloid burdenDaily Living ScaleEvidence of amyloidCDR-SB scoresYears of ageMild cognitive impairmentIgG1 monoclonal antibodyTracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease?
Tosin M, Simuni T, Stebbins G, Cedarbaum J. Tracking Emergence of New Motor and Non-Motor Symptoms Using the MDS-UPDRS: A Novel Outcome Measure for Early Parkinson’s Disease? Journal Of Parkinson’s Disease 2022, 12: 1345-1351. PMID: 35466955, PMCID: PMC9198734, DOI: 10.3233/jpd-223170.Peer-Reviewed Original ResearchConceptsEmergent symptomsDisease progressionOutcome measuresParkinson's disease clinical trialsNon-motor symptomsEarly Parkinson's diseaseDaily Living ScalePatient-reported experiencesClinical rating scalesNovel outcome measuresSymptomatic treatmentPD progressionClinical trialsMedian numberDaily livingLiving ScaleParkinson's diseaseSummary scoresMDS-UPDRSUseful markerRating ScaleSTX groupProgressionStxSymptomsThe Effect of Dual Sensory Impairment and Multimorbidity Patterns on Functional Impairment: A Longitudinal Cohort of Middle-Aged and Older Adults in China
Wang Q, Zhang S, Wang Y, Zhao D, Chen X, Zhou C. The Effect of Dual Sensory Impairment and Multimorbidity Patterns on Functional Impairment: A Longitudinal Cohort of Middle-Aged and Older Adults in China. Frontiers In Aging Neuroscience 2022, 14: 807383. PMID: 35462686, PMCID: PMC9028763, DOI: 10.3389/fnagi.2022.807383.Peer-Reviewed Original ResearchDual sensory impairmentDaily Living ScaleMultimorbidity patternsFunctional impairmentSensory impairmentOlder adultsLiving ScaleCo-existing diseasesRetirement Longitudinal StudyMultimorbidity prevalenceFunctional statusLongitudinal cohortADL limitationsIADL limitationsInstrumental activitiesMultimorbidityRespiratory patternIntegrated careChina HealthImpairmentLongitudinal studyAdultsPrevalenceSelf-report measuresPotent pathway
2021
Randomized controlled trial of gamma sensory stimulation treatment maintains functional ability and decreases sleep fragmentation in Alzheimer’s disease patients
Cimenser A, Hempel E, Travers T, Strozewski N, Malchano Z, Hajos M. Randomized controlled trial of gamma sensory stimulation treatment maintains functional ability and decreases sleep fragmentation in Alzheimer’s disease patients. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056599.Peer-Reviewed Original ResearchADCS-ADL scoresSleep qualityFunctional abilityAlzheimer's diseaseTreatment groupsSham groupDisease patientsAD patientsAlzheimer's Disease Cooperative Study-ActivitiesSensory stimulationSensory stimulation treatmentAD-related pathologySubgroup of patientsDaily Living ScaleImproved sleep qualityModerate Alzheimer's diseaseNew therapeutic approachesAlzheimer's disease patientsSensory stimulation therapyOpposite changesConclusions PatientsMethods PatientsSleep fragmentationClinical trialsTreatment periodSensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients
Cimenser A, Hempel E, Travers T, Strozewski N, Martin K, Malchano Z, Hajós M. Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients. Frontiers In Systems Neuroscience 2021, 15: 746859. PMID: 34630050, PMCID: PMC8500065, DOI: 10.3389/fnsys.2021.746859.Peer-Reviewed Original ResearchActive treatment groupHz gamma oscillationsAlzheimer's diseaseSensory stimulationSham groupDisease patientsAD patientsTreatment groupsFunctional abilityAlzheimer's Disease Cooperative Study-ActivitiesGamma oscillationsADCS-ADL scoresDisease-modifying propertiesAdditional clinical benefitBeneficial clinical effectsDaily Living ScaleActive treatment patientsModerate Alzheimer's diseaseAlzheimer's disease patientsNormal neuronal functionDaily living activitiesEyes-closed conditionsSensory stimulation therapyDaily therapyGroup patients
2011
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77: 1253-1262. PMID: 21917766, PMCID: PMC3179648, DOI: 10.1212/wnl.0b013e3182309fa5.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4Dose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansInositolMagnetic Resonance ImagingMaleMental Status ScheduleMiddle AgedPeptide FragmentsPlatelet Aggregation InhibitorsTime FactorsTreatment OutcomeConceptsNeuropsychological test batteryAlzheimer's diseaseDose-ranging phase 2 studyAlzheimer's Disease Cooperative Study-ActivitiesClass II trialsClinical efficacy outcomesCSF biomarker resultsScyllo-inositol concentrationsPhase 2 studyPrimary efficacy analysisHigh-dose groupDaily Living ScaleBrain ventricular volumeCoprimary endpointsEarly discontinuationEfficacy outcomesII trialADCS-ADLDose groupEfficacy analysisAcceptable safetyAβx-42Living ScaleOptimal doseTreatment groupsSuitability of the Clinical Dementia Rating‐Sum of Boxes as a single primary endpoint for Alzheimer's disease trials
Coley N, Andrieu S, Jaros M, Weiner M, Cedarbaum J, Vellas B. Suitability of the Clinical Dementia Rating‐Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimer's & Dementia 2011, 7: 602-610.e2. PMID: 21745761, DOI: 10.1016/j.jalz.2011.01.005.Peer-Reviewed Original ResearchConceptsClinical Dementia Rating SumCo-primary endpointsPrimary endpointSingle primary endpointCDR-SBInternal responsivenessFunctional impairmentADAS-CogDisease trialsExternal responsivenessAlzheimer's diseaseAlzheimer's Disease Assessment Scale-cognitive subscaleFloor/ceiling effectsCDR-SB changeDisease-modifying trialsModerate AD patientsDaily Living ScaleAlzheimer's disease trialsConvergent validityInternal consistencyAD trialsDisease stageAD patientsInstrumental activitiesMean change
2008
Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older Men
Han L, Agostini JV, Allore HG. Cumulative Anticholinergic Exposure Is Associated with Poor Memory and Executive Function in Older Men. Journal Of The American Geriatrics Society 2008, 56: 2203-2210. PMID: 19093918, PMCID: PMC3952110, DOI: 10.1111/j.1532-5415.2008.02009.x.Peer-Reviewed Original ResearchConceptsTotal anticholinergic burdenCumulative anticholinergic exposureOlder menAnticholinergic medicationsAnticholinergic burdenAnticholinergic exposureCumulative exposureVeterans Affairs primary care clinicsExecutive functionAnticholinergic medication useDeleterious adverse effectsProspective cohort studySeverity of hypertensionCommunity-dwelling menPrimary care clinicsDaily Living ScalePotential risk factorsPrescription of drugsAnticholinergic scoreCohort studyMultiple medicationsAnticholinergic effectsMedication useCare clinicsPhysical function
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply